MicroPort Scientific Corporation

MicroPort Scientific Corporation

MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai. The company produces a broad range of medical devices covering cardiovascular, orthopedic, cardiac rhythm management, electrophysiology, endovascular, neurovascular, surgical robots, and surgical device solutions. The firm invests heavily in R&D and manufacturing. It targets multiple therapeutic areas: coronary artery disease, joint replacement, arrhythmias, stroke, aortic stenosis, aortic aneurysm, and arteriosclerosis. MicroPort's portfolio includes devices for both developed and emerging market healthcare systems. The company operates globally, with a presence in China, Europe (Germany, France, Italy, United Kingdom, Türkiye), Japan, and the United States. MicroPort has structured itself as a public company on the Hong Kong Stock Exchange, with investor relations material including financial reports, presentations, and stock charts. It maintains a corporate governance framework and publishes annual financial information. The company employs thousands worldwide, though exact headcount is not publicly disclosed on its site. A recent development: the firm continues to expand its global regulatory clearances and product approvals (per company filings, 2025–2026). A structural differentiator is MicroPort's breadth across multiple high-regulation medical specialties under one publicly traded entity, similar to a conglomerate. This scale allows cross-subsidization of R&D between faster- and slower-growing segments. Its focus on mastering minute details in device engineering aligns with its stated mission of universal access to life-changing technology, though precise investment or capital deployment figures remain undisclosed.